Renal nitric oxide production is decreased in diabetics rats and improved by AT1 receptor blockade

Journal of Hypertension

Volumn 22, Issue 8, 2004, Pages 1571-1577

  Awad, Alaa S ^a   Webb, Randy L ^b   Carey, Robert M ^a,c   Siragy, Helmy M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiotensin II; Angiotensin subtype 1 receptor; Losartan; Nitric oxide; Valsartan

Indexed keywords

ALBUMIN; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GLUCOSE; LOSARTAN; NITRIC OXIDE; STREPTOZOCIN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; GLUCOSE BLOOD LEVEL; INTERSTITIAL FLUID; KIDNEY CORTEX; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

EID: 3843140495     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000133718.86451.6a     Document Type: Article

References (47)

1. Navar GL, Imig ID, Zou L, Wang GT. Intrarenal production of angiotensin II. Semin Nephrol 1997; 17:412-422.
2. Wu F, Park F, Cowley AW Jr, Mattson DL. Quantification of nitric oxide synthase activity in microdissected segments of the rat kidney. Am J Physiol 1999; 276:F874-F881.
3. Siragy HM, El-Kersh MA, Gasparo M De, Webb RL, Carey RM. Differences in AT2-receptor stimulation between AT1-receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. J Hypertens 2002; 20:1157-1163.
4. Komers R, Allen TJ, Cooper ME. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 1994; 43:1190-1197.
5. Mattar AL, Fujihara CK, Ribeiro MO, Nucci G de, Zatz R. Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. Nephron 1996; 74:136-143.
6. Maree A, Peer G, Iaina A, Slum M, Wollman Y, Csernihovsky T, et al. Nitric oxide in streptozotocin-induced diabetes mellitus in rats. Clin Sci 1996; 90:379-384.
7. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM. Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am J Physiol 1993; 265:F886-F895.
8. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 1993; 43:1306-1312.
9. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96:25-28.
10. Thorup C, Ollerstam A, Persson AE, Torffvit O. Increased tubuloglomerular feedback reactivity is associated with increased NO production in the streptozotocin-diabetic rat. J Oiabet Compilc 2000; 14:46-52.
11. Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, et al. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 2001; 12:1630-1639.
12. Piper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 1998; 31:1047-1060.
13. Trachtman H, Futterweit S, Pine E, Mann J, Valderrama E. Chronic diabetic nephropathy: role of inducible nitric oxide synthase. Pediatr Nephrol 2002; 17:20-29.
14. Keynan S, Hirshberg B, Levin-Iaina N, Wexler ID, Dahan R, Reinhartz E, et al. Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int 2000; 58:740-747.
15. Madeddu P. Angiotensin AT1 receptor blockers: a heterogeneous family on kidney perspective. J Hypertens 2002; 20:1065.
16. Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest 1996;97:1978-1982.
17. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100:264-269.
18. Siragy HM, Awad A, Abadir P, Webb R. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats. Endocrinology 2003; 144:2229-2233.
19. Siragy HM, Gasparo M de, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertens 2000; 35:1074-1077.
20. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000; 36:449-467.
21. Anderson S, Jung FF, Inglefinger JR. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265:F477-F486.
22. Brands MW, Fitzgerald SM. Blood pressure control early in diabetes: A balance between angiotensin II and nitric oxide. Clin Exp Pharm Physiol 2002;29:127-131.
23. Jandeleit K, Rumble J, Jackson B, Cooper ME. Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus. Clin Exp Pharm Physiol 1992; 19:343-347.
24. Brands MW, Hopkins TE. Poor glycemic control induced hypertension in diabetes mellitus. Hypertension 1996; 27:753-759.
25. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 1999; 10:1778-1785.
26. Tatchum-Talom R, Gopalakrishnan V, McNeill JR. Radiotelemetric monitoring of blood pressure and mesenteric arterial bed responsiveness in rats with streptozotocin-induced diabetes. Can J Physiol Pharm 2000; 78:721-728.
27. Brands MW, Fitzgerald SM, Hewitt WH, Hailman AE. Decreased cardiac output at the onset of diabetes: renal mechanisms and peripheral vasoconstriction. Am J Physiol 2000; 278:E917-E924.
28. Veelken R, Hilgers KF, Mariner A, Haas A, Bohmer KP, Sterzel RB. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 2000; 11:71-79.
29. Wang YX, Brooks DP, Edwards RM. Attenuated glomerular cGMP production and renal vasodilation in streptozotocin-induced diabetic rats. Am J Physiol 1993; 264:R952-R956.
30. Yu WJ, Juang SW, Chin WT, Chi TC, Chang CJ, Cheng JT. Insulin restores neuronal nitric oxide synthase expression in streptozotocin-induced diabetic rats. Life Sci 2000; 68:625-634.
31. Craven PA, Studer RK, DeRubertis FR. Impaired nitric oxide release by glomeruli from diabetic rats. Metabolism 1995; 44:695-698.
32. Craven PA, Studer RK, DeRubertis FR. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of cholinergic response. J Clin Invest 1994; 93:311-320.
33. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88:E14-E22.
34. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87:432-438.
35. Verbeke P, Perichon M, Friguet B, Bakala H. Inhibition of nitric oxide synthase activity by early and advanced glycation end products in cultured rabbit proximal tubular epithelial cells. Biochim Biophys Acta 2000; 502:481-494.
36. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108:1341-1348.
37. Yagihashi N, Nishida N, Seo HG, Taniguchi N, Yagihashi S. Expression of nitric oxide synthase in macula densa in streptozotocin diabetic rats. Diabetologia 1996; 39:793-799.
38. Vernet D, Cai L, Garban H. Babbitt ML, Murray FT, Rajfer J, Gonzalez-Cadavid NF. Reduction of penile nitric oxide synthase in diabetic BB/ WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995; 136:5709-5717.
39. Brodsky SV, Morrishow AM, Dharia N, Gross SS, Goligorsky MS. Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol 2001; 280:F480-F486.
40. Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Bums KD. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 2001; 280:F254-F265.
41. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23:439-449.
42. Gasparo M de, Whitebread S. Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept 1995; 59:303-311.
43. Müller P, Flesch G, Gasparo M de, Gasparini M, Howald H. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharm 1997; 52:441-449.
44. Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999; 15:26F-28F.
45. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharm Exp Ther 1990; 255:211-217.
46. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83:1333-1342.
47. Verheijen I, Fierens FL, Debacker JP, Vauquelin G, Vanderheyden PM. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. Fundam Clin Pharm 2000; 14:577-585.